• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在心血管疾病高危人群中,初级预防工作开展得很差:来自欧洲心脏病学会 EURObservational Research Programme EUROASPIRE V 调查的 16 个欧洲国家的报告。

Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.

机构信息

St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.

National Institute for Prevention and Cardiovascular Health, National University of Ireland-Galway, Republic of Ireland.

出版信息

Eur J Prev Cardiol. 2021 May 8;28(4):370-379. doi: 10.1177/2047487320908698. Epub 2020 Mar 20.

DOI:10.1177/2047487320908698
PMID:33966079
Abstract

BACKGROUND

European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V in primary care was carried out by the European Society of Cardiology EURObservational Research Programme in 2016-2018. The main objective was to determine whether the 2016 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been implemented in clinical practice.

METHODS

The method used was a cross-stional survey in 78 centres from 16 European countries. Patients without a history of atherosclerotic cardiovascular disease either started on blood pressure and/or lipid and/or glucose lowering treatments were identified and interviewed ≥ 6 months after the start of medication.

RESULTS

A total of 3562 medical records were reviewed and 2759 patients (57.6% women; mean age 59.0 ± 11.6 years) interviewed (interview rate 70.0%). The risk factor control was poor with 18.1% of patients being smokers, 43.5% obese (body mass index ≥30 kg/m2) and 63.8% centrally obese (waist circumference ≥88 cm for women, ≥102 cm for men). Of patients on blood pressure lowering medication 47.0% reached the target of <140/90 mm Hg (<140/85 mm Hg in people with diabetes). Among treated dyslipidaemic patients only 46.9% attained low density lipoprotein-cholesterol target of <2.6 mmol/l. Among people treated for type 2 diabetes mellitus, 65.2% achieved the HbA1c target of <7.0%.

CONCLUSION

The primary care arm of the EUROASPIRE V survey revealed that large proportions of people at high cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids and diabetes. Thus, the potential to reduce the risk of future cardiovascular disease throughout Europe by improved preventive cardiology programmes is substantial.

摘要

背景

欧洲心脏病学会欧洲观察性研究计划(EURObservational Research Programme)于 2016-2018 年在初级保健中开展了二级和一级预防以减少事件的干预(EUROASPIRE V)。主要目的是确定 2016 年联合欧洲学会心血管疾病高危人群心血管疾病预防指南是否已在临床实践中得到实施。

方法

采用 2016 年 16 个欧洲国家 78 个中心的横断面调查方法。确定无动脉粥样硬化性心血管疾病史的患者开始使用降压和/或降脂和/或降糖药物治疗,并在开始药物治疗后≥6 个月对其进行采访。

结果

共审查了 3562 份病历,对 2759 名患者(57.6%为女性;平均年龄 59.0±11.6 岁)进行了采访(采访率为 70.0%)。危险因素控制不佳,18.1%的患者吸烟,43.5%肥胖(体重指数≥30kg/m2),63.8%中心性肥胖(女性腰围≥88cm,男性腰围≥102cm)。接受降压药物治疗的患者中,47.0%达到<140/90mmHg 的目标(糖尿病患者<140/85mmHg)。在接受调脂治疗的患者中,只有 46.9%达到低密度脂蛋白胆固醇<2.6mmol/l 的目标。在接受 2 型糖尿病治疗的人群中,65.2%达到 HbA1c<7.0%的目标。

结论

EUROASPIRE V 调查的初级保健部分显示,很大一部分心血管疾病高危人群生活方式不健康,血压、血脂和糖尿病控制不足。因此,通过改善预防心脏病学计划,在整个欧洲降低未来心血管疾病风险的潜力巨大。

相似文献

1
Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.在心血管疾病高危人群中,初级预防工作开展得很差:来自欧洲心脏病学会 EURObservational Research Programme EUROASPIRE V 调查的 16 个欧洲国家的报告。
Eur J Prev Cardiol. 2021 May 8;28(4):370-379. doi: 10.1177/2047487320908698. Epub 2020 Mar 20.
2
Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.心血管疾病高危人群的生活方式与风险因素管理。欧洲心脏病学会关于欧洲通过干预进行二级和一级预防以减少事件行动(EUROASPIRE)IV在14个欧洲地区开展的横断面调查的报告。
Eur J Prev Cardiol. 2016 Dec;23(18):2007-2018. doi: 10.1177/2047487316667784. Epub 2016 Sep 27.
3
Challenge of cardiovascular prevention in primary care: achievement of lifestyle, blood pressure, lipids and diabetes targets for primary prevention in England - results from ASPIRE-3-PREVENT cross-sectional survey.初级保健中心血管预防面临的挑战:英格兰初级预防中实现生活方式、血压、血脂和糖尿病目标 - ASPIRE-3-PREVENT 横断面调查结果。
Open Heart. 2024 Oct 15;11(2):e002704. doi: 10.1136/openhrt-2024-002704.
4
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.欧洲动脉粥样硬化调查项目IV:欧洲心脏病学会对来自24个欧洲国家的冠心病患者的生活方式、危险因素及治疗管理情况的调查。
Eur J Prev Cardiol. 2016 Apr;23(6):636-48. doi: 10.1177/2047487315569401. Epub 2015 Feb 16.
5
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.27 个国家的冠心病患者生活方式及对心血管危险因素控制的影响:欧洲心脏病学会 ESC-EORP EUROASPIRE V 注册研究结果。
Eur J Prev Cardiol. 2019 May;26(8):824-835. doi: 10.1177/2047487318825350. Epub 2019 Feb 10.
6
EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.欧洲冠心病二级预防调查(EUROASPIRE):主要结果。EUROASPIRE研究组。通过干预减少事件的欧洲二级预防行动。
Eur Heart J. 1997 Oct;18(10):1569-82. doi: 10.1093/oxfordjournals.eurheartj.a015136.
7
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.日常实践中的心血管疾病预防指南:八个欧洲国家的EUROASPIRE I、II和III调查比较
Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5.
8
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.欧洲动脉粥样硬化调查III:对来自22个欧洲国家的冠心病患者的生活方式、风险因素及心脏保护药物治疗使用情况的调查。
Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37. doi: 10.1097/HJR.0b013e3283294b1d.
9
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.来自15个国家的冠心病患者的生活方式、危险因素管理及药物治疗的应用;欧洲心脏调查项目EUROASPIRE II的主要结果
Eur Heart J. 2001 Apr;22(7):554-72. doi: 10.1053/euhj.2001.2610.
10
Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry.冠心病患者危险因素控制的性别差距远未缩小:来自欧洲心脏病学会 EUROASPIRE V 注册研究的结果。
Eur J Prev Cardiol. 2022 Mar 11;29(2):344-351. doi: 10.1093/eurjpc/zwaa144.

引用本文的文献

1
Low-Density Lipoprotein Cholesterol Target Attainment in Lithuania: A Nationwide Analysis of Real-World Health Data.立陶宛低密度脂蛋白胆固醇目标达成情况:基于真实世界健康数据的全国性分析
Medicina (Kaunas). 2025 Aug 19;61(8):1484. doi: 10.3390/medicina61081484.
2
Protocol for the OPTIMSE-1 randomised clinical trial to test specialist-led identification and management of cardio-renal-metabolic-pulmonary disease in machine learning algorithm-detected high-risk community-dwelling individuals.OPTIMSE-1随机临床试验方案,用于测试在机器学习算法检测出的高危社区居住个体中,由专科医生主导的心肾代谢性肺病识别与管理。
BMJ Open. 2025 Aug 6;15(8):e101088. doi: 10.1136/bmjopen-2025-101088.
3
Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention.
初级预防中的心血管风险评估及降脂治疗建议
J Clin Med. 2025 Mar 25;14(7):2220. doi: 10.3390/jcm14072220.
4
Conceptual model of pharmaceutical care for patients with coronary heart disease and comorbid conditions in Ukraine.乌克兰冠心病合并症患者药学服务的概念模型
J Pharm Policy Pract. 2025 Apr 8;18(1):2484577. doi: 10.1080/20523211.2025.2484577. eCollection 2025.
5
Interactive Effects of Weight Recording Frequency and the Volume of Chat Communication With Health Care Professionals on Weight Loss in mHealth Interventions for Noncommunicable Diseases: Retrospective Observational Study.体重记录频率与与医护人员聊天沟通量对非传染性疾病移动健康干预中体重减轻的交互作用:回顾性观察研究。
Interact J Med Res. 2025 Mar 27;14:e65863. doi: 10.2196/65863.
6
Research of affordability to essential medicines for coronary heart disease in Ukraine.乌克兰冠心病基本药物可及性研究。
J Pharm Policy Pract. 2025 Mar 11;18(1):2470841. doi: 10.1080/20523211.2025.2470841. eCollection 2025.
7
Promoting lifestyle change through text messages to patients with hypertension: A randomized controlled trial in Swedish primary care.通过短信促进高血压患者的生活方式改变:瑞典初级保健中的一项随机对照试验。
Prev Med Rep. 2025 Feb 17;51:103009. doi: 10.1016/j.pmedr.2025.103009. eCollection 2025 Mar.
8
Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database.2型糖尿病患者的降脂治疗与低密度脂蛋白目标达成情况:来自意大利糖尿病专科医生协会数据库的趋势
Cardiovasc Diabetol. 2025 Feb 28;24(1):94. doi: 10.1186/s12933-025-02648-1.
9
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy.一级预防中医生认知的心血管风险与计算得出的心血管风险之间的差异:对低密度脂蛋白胆固醇(LDL-C)目标达成及适当降脂治疗的影响。
High Blood Press Cardiovasc Prev. 2025 Mar;32(2):199-208. doi: 10.1007/s40292-025-00705-0. Epub 2025 Feb 19.
10
Fifteen-year trends in diabetes drug management and control in French-speaking Switzerland.瑞士法语区糖尿病药物管理与控制的十五年趋势
Diabetol Metab Syndr. 2025 Feb 12;17(1):56. doi: 10.1186/s13098-025-01620-z.